Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia

Leukemia & Lymphoma
Jolanta PerzA D Ho

Abstract

Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymphomas and normal B-cells. Previous experience with rituximab treatment in small series of patients with B-CLL suggest that it is less effective in B-CLL than in follicular lymphomas. We analyzed the correlation between CD20-expression level and efficacy of rituximab treatment in eight patients with refractory or relapsed B-CLL and two patients with B-cell prolymphocytic leukemia (B-PLL). We could not identify any correlation between CD20-expression and efficacy of rituximab treatment.

Citations

Jan 14, 2003·Hematological Oncology
May 5, 2005·Current Treatment Options in Oncology·Ahmed AbsiMatt Kalaycio
Mar 23, 2005·Critical Reviews in Oncology/hematology·M Stern, R Herrmann
Oct 1, 2009·Expert Reviews in Molecular Medicine·John C Morris, Thomas A Waldmann
Jun 26, 2007·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·Falko Fend, Markus Kremer
Feb 4, 2011·OncoTargets and Therapy·Alessandra TedeschiMarco Montillo
Oct 19, 2005·Virchows Archiv : an International Journal of Pathology·Marcus KremerFalko Fend
May 17, 2014·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Xinfeng LinZhi Yang
Apr 12, 2003·Leukemia & Lymphoma·Giovanni D'ArenaMichael J Keating
Apr 23, 2004·Leukemia & Lymphoma·Tadeusz Robak
Aug 15, 2003·Leukemia & Lymphoma·Giovanni D'ArenaNicola Di Renzo
Nov 30, 2010·Best Practice & Research. Clinical Haematology·Edward D Ball, H Elizabeth Broome
Feb 5, 2008·Progress in Histochemistry and Cytochemistry·Falko FendStephan Dirnhofer
Mar 26, 2004·Seminars in Oncology·Peter Hillmen
Dec 8, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Matt E KalaycioMukta Arora
Dec 2, 2010·Blood·Emilio Iannitto, Claudio Tripodo
Apr 18, 2006·Seminars in Oncology·Biju KrishnanClaire Dearden
Dec 13, 2006·American Journal of Hematology·Bassem T Chaar, Paul J Petruska
Oct 13, 2012·Medicinal Research Reviews·Rangaiah ShashidharamurthyPeriasamy Selvaraj
Jun 20, 2018·Frontiers in Oncology·Timothy M PierpontKristy L Richards
Jul 5, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tom van MeertenSaskia B Ebeling
Jul 3, 2008·Cancer Research·Christian Meyer zum BüschenfeldeChristian Peschel
Feb 4, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stéphane DalleCharles Dumontet

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.